drugset / Trial / NCT04551885
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
This is a Phase 1 dose-finding study of FT-516 in combination with monoclonal antibodies in participants with advanced solid tumors. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Timeline
- Start
- 2020-09-07
- Primary completion
- 2023-08-11
- Completion
- 2023-08-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FT516 | Cell therapy | — | — |
| Background | Avelumab | Monoclonal antibody | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |
| Background | aldesleukin | Protein / enzyme biologic | — | — |